Search

Supplemental Digital Content is available in the text.

The Michigan State Housing Development Authority offers a graduate purchase assistance program meant to get graduates into their first home. People who have received their diplomas (bachelor's, associate's, master's or [...]

First it was the baby boomers. Then Generation X. Now it's time for the millennials to take center stage. For a struggling Michigan economy, finding out what this group needs [...]

Even if National Football League Commissioner Roger Goodell named Detroit as the permanent home of the Super Bowl, it might not have as big an economic payoff to the region [...]

If Arizona homeowners agree to pay less than the price of a Big Mac and a soft drink a year, poor elderly can receive a slight decrease in the cost [...]

ABSTRACTIncreasing attention has been paid to developability assessment with the understanding that thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid delays during late-stage development. The concept of developability is based on the knowledge gained from the successful development of approximately 80 marketed antibody and Fc-fusion protein drug products and from the lessons learned from many failed development programs over the last three decades. Here, we reviewed antibody quality attributes that are critical to development and traditional and state-of-the-art analytical methods to monitor those attributes. Based on our collective experiences, a practical workflow is proposed as a best practice for developability assessment including in silico evaluation, extended characterization and forced degradation using appropriate analytical methods that allow characterization with limited material consumption and fast turnaround time.

ABSTRACTProcess changes are inevitable in the life cycle of recombinant monoclonal antibody therapeutics. Products made using pre- and post-change processes are required to be comparable as demonstrated by comparability studies to qualify for continuous development and commercial supply. Establishment of comparability is a systematic process of gathering and evaluating data based on scientific understanding and clinical experience of the relationship between product quality attributes and their impact on safety and efficacy. This review summarizes the current understanding of various modifications of recombinant monoclonal antibodies. It further outlines the critical steps in designing and executing successful comparability studies to support process changes at different stages of a product's lifecycle.